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Background/Aim: The patients with cystic fibrosis (CF) are living longer compared to the past, but respiratory failure is still the most
common cause of mortality. The aim of this study is to investigate factors associated with severe lung disease in a cohort of adult patients
with CF.
Materials and methods: Demographic data, clinical and laboratory findings of the patients aged 18 years and more were collected and
the patients were grouped according to forced expiratory volume in 1 s (FEV1) as severe group: <40% and nonsevere ≥40%. Associations
were investigated between groups and clinical outcomes.
Results: A total of 76 patients were enrolled in the study. The mean age was 24.5 ± 5.25 years and 36 (47.4%) patients were female. In the
severe group; the mean age was higher (27.1 ± 6.0 vs 23.6 ± 4.7, P = 0.013), the median Chrispin-Norman score of severe lung disease
group was higher (14 (6–22) vs 5.5 (0–20), P < 0.001), hospitalization at least once in a year for intravenous antibiotic was more common
(12/18 (66%) vs 19/58 (32%), P = 0.014). There was a positive correlation between body mass index (BMI) and lung function, indicating
that lower nutritional status was related to lower FEV1, r2 = 0.21, P < 0.001. The median FEV1% was lower in patients with CF-related
diabetes (38 (14–95) vs 66 (13–121), P = 0.042). Dornase alpha use and physiotherapy rate were higher in severe lung disease group (P
= 0.008 and P < 0.001, respectively).
Conclusion: Lower BMI, older age, presence of CF-related diabetes, higher radiologic scores, use of dornase alpha and physiotherapy
and higher hospitalization rate for intravenous antibiotic therapy are significantly associated with severe lung disease.
Key words: Adult, cystic fibrosis, severe lung disease, risk factors

1. Introduction
With advanced multidisciplinary care, nutritional support,
and new therapeutic options, median survival rate has
increased in patients with cystic fibrosis (CF) [1]. This
condition has such a considerable effect that the number of
adult patients with CF is now greater than the number of
children in many developed countries [2,3]. Cystic fibrosis
is a chronic and progressive disease that has an increasingly
complex course in adulthood [4]. As a result of a chronic
progressive illness, many disease- and treatment-related
complications such as pulmonary exacerbations, massive
hemoptysis, pneumothorax, cystic fibrosis-related diabetes,
metabolic bone disease, adverse effects of medications,

and psychological issues are more common in adulthood.
However, respiratory failure is still the most common cause
of mortality as observed in childhood population [5]. There
are several methods such as spirometry, imaging, and lung
clearance index to assess the severity of lung disease [6].
Spirometry is still the most commonly used method in
registries for evaluating lung functions [2,3]. Determining
the factors associated with severe lung disease may help to
identify preventable and treatable risk factors associated
with morbidity and mortality. There are no studies
investigating risk factors related to poor lung capacity in
Turkish adult population with CF as a developing country
that has already established a registry system for CF [7].
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With this study, as a newly established adult CF unit,
we aimed to investigate clinical features of our adult
population with CF and possible risk factors related with
worse lung function.
2. Material and methods
2.1. Patients and methods
All patients over 18 years old with a confirmed diagnosis
of CF (with a positive sweat test; sweat chloride ≥60
mmol/L) who were followed up in our adult CF unit
between January 2014 and December 2015 were enrolled
in this study. The data were collected during regular
patient care. All patients gave informed consent for
scientific use of the data. At the end of the enrollment
period, a cross-sectional analysis was performed for
investigating factors associated with severe lung disease.
The demographic (age, sex), clinical and laboratory
data (age at the time of diagnosis, the best value of
body mass index (BMI) of the previous year, type of
genetic mutation, sputum cultures, maximum value
of forced expiratory volume in one second percent
predicted (FEV1%) within the previous year, current
comorbidities such as diabetes, pancreatic insufficiency,
metabolic bone disease (osteopenia, osteoporosis),
allergic bronchopulmonary aspergillosis (ABPA), the
medical history (use of inhaled antibiotics, pancreatic
enzyme replacement therapy, insulin, supplemental
vitamins, pulmonary rehabilitation methods) and
adverse reactions to drugs), number of hospitalization
for intravenous antibiotic in the previous year were
recorded. Genetic mutation analysis has been performed
by sequence analysis since January 2015 in our hospital.
Chrispin-Norman score was used for assessing the
severity of lung disease using chest radiography [8].
Patients were divided into two groups based on FEV1%
predicted value: group 1, severe lung disease with FEV1
<40%; group two, nonsevere lung disease with FEV1
≥40%. These two groups were compared in terms of
demographic, genetic, microbiological, laboratory
features, comorbidity, medical therapy, and BMI. The
patients were accepted as chronically infected with
Pseudomonas aeruginosa or Staphylococcus aureus if these
microorganisms were isolated in ³50% of routine sputum
cultures during the study period [9]. Body mass index was
categorized as <18.5, 18.5–22, 22–25, ³25 corresponding
to underweight, risky, normal weight and overweight,
respectively. Target BMI was accepted to be >22 kg/m2
for women and >23 kg/m2 for men [2]. Additionally, the
median FEV1 value of the patients chronically infected
with Pseudomonas aeruginosa and the patients with
diabetes were compared with the patients who did not
have these conditions. The study protocol was approved
by the Ethics Committee at Hacettepe University (GO
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15/146-39) and all participants provided informed
consent in the format required by the relevant board.
2.2. Statistical analyses
We analyzed data with SPSS version 23.0.0.2 (SPSS,
Chicago, Illinois, United States). We used mean and
standard deviation for normally distributed continuous
variables (age, BMI), median and minimum, maximum
for nonnormally distributed data (age of diagnosis,
FEV1, Chrispin-Norman score, hospitalization rate) and
percentage for categorical variables. The Student’s t-test for
independent samples was performed to compare means
of age, and BMI between severe and nonsevere groups.
Comparisons were made for continuous variables such as
age of diagnosis, radiologic scores, hospitalization rates
using the nonparametric Mann–Whitney test. Fisher’s
exact test and chi-squared test were utilized for categorical
comparisons of sex, comorbidity status such as diabetes,
pancreatic insufficiency, presence of F508del mutation,
chronic P. aeruginosa and S. aureus infection status,
hospitalization at least once in a year, physiotherapy rate,
and dornase alfa use. Additionally, median FEV1 values
between patients with diabetes and nondiabetes were
compared using the Mann–Whitney test. Correlations
between FEV1 and BMI values were calculated using the
Spearman correlation.
3. Results
3.1. Patients
A total of 76 patients followed up in the study period were
enrolled. Seventy-four patients (97.3%) were transferred
from the department of pediatric pulmonology to adult
CF unit. The mean age was 24.5 ± 5.25 years and male
to female ratio was 1.1 (40/36 patients). The baseline
characteristics of the patients are shown in Table 1. The
median age at diagnosis was 96 (8.75–177) months and
22% were offspring of consanguineous marriage. Ten
patients (13%) were diagnosed at adulthood.
A total of 59 (77.6%) patients had genetic mutations.
Of these, 39.4% were heterozygous for F508del and 14.4%
were homozygous for F508del mutation. One-third of
the patients were homozygous for a class I-III mutation.
The median FEV1% predicted was 64.5 (13–121) and it
was below 40 percentile in 18 (23.7%) patients. The mean
BMI was 21 ± 3.82 kg/m2. Forty-eight (63.2%) patients
had BMI below the targeted value and 18 (23.7%) patients
were categorized as underweight. There was no patient
receiving enteral nutrition support via nasogastric or
gastrostomy tube. The medical history of the patients is
summarized in Table 2.
There was no lung transplant recipient in the study
group, but 12 (15.8%) patients were on waiting list due
to low FEV1% predicted (below 30%), recurrent severe
hemoptysis or frequent pulmonary exacerbations.
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Table 1. Demographic and clinical characteristics of patients.

Table 2. Medical history.

n = 76

n (%)

Age (years); mean ± SD

24.5 ± 5.25

Pancreatic enzyme replacement

67 (82)

Female, n (%)

36 (47.4)

Enteral nutrition support

23 (30.3)

Multivitamin

53 (69.7)

Age at diagnosis of CF (months);
median (range)

96 (8.75–177)

Dornase alpha

53 (69.7)

Diagnosis over 18 years, n (%)

10 (13.1)

Bronchodilator

28 (36.8)

FEV1 % predicted; median (min, max)

64.5 (13, 121)

Inhaled steroid

22 (28.9)

BMI (kg/m2), mean ± SD

21 ± 3.82

Inhaled tobramycin

26 (34)

CFTR mutation (%)
Class I-III homozygous

Inhaled colistin

16 (21)

33

Long term oxygen therapy

8 (10.5)

At least 1 Class IV-V mutation, n (%)

24

Oral steroid / itraconazol

7 (9.2)

Unidentified/other, n (%)

43

Omalizumab

2 (2.7)

F508del homozygous, n (%)

11 (14.4)

Insulin

11 (14.3)

Chronic PsA infection, n (%)

23 (48.9)

Pulmonary rehabilitation (%)

Chronic S. aureus infection, n (%)

27 (57.4)

PEP-Flutter

30

MRSA, n (%)

2 (2.6)

Postural drainage

20

A. fumigatus, n (%)

18 (23.6)

HCWO

3

Achromobacter spp., n (%)

7 (9.2)

None

47

S. maltophilia, n (%)

5 (6.5)

Nontuberculous mycobacteria, n (%)

4 (5.2)

Pancreatic insufficiency, n (%)

67 (88.2)

ABPA, n (%)

9 (11.8)

CFRD, n (%)

11 (14.5)

Metabolic bone disease, n (%)

27 (35.5)

Nasal polip and sinus disease, n (%)

18 (23.7) / 48 (63.2)

Liver disease, n (%)

28 (36.8)

Nephrolithiasis, n (%)

3 (3.9)

Pancreatitis, n (%)

2 (2.6)

Hemoptysis, n (%)

31 (40.8)

Pneumothorax, n (%)

4 (5.3)

Drug allergies, n (%)

13 (17.1)

n= number, SD= standard deviation, BMI= body mass index,
FEV1= forced expiratory volume in 1 s, min= minimum, max=
maximum, ABPA= allergic bronchopulmonary aspergillosis,
CFRD= cystic fibrosis related diabetes, PsA= Pseudomonas
aeruginosa, S. aureus= Staphylococcus aureus, MRSA= Meticilin
resistant Staphylococcus aureus, A. fumigatus= Aspergillus
fumigatus, S. maltophilia= Stenotrophomonas maltophilia,
CFTR= cystic fibrosis transmembrane regulator

3.2. Severe lung disease and associated factors
The median FEV1 values of females and males were 59.5
(14–121) and 67 (13–104), respectively (P = 0.8). The
mean age of the severe lung disease group was higher

n= number, PEP= positive end expiratory pressure, HCWO=
high frequency chest wall oscillation

than the nonsevere group (27.1 ± 6.0 vs 23.6 ± 4.7, p=
0.013). Three of ten patients diagnosed at adulthood had
severe lung disease. There was no statistical difference in
age of diagnosis between severe and nonsevere groups
(102 months (5–384) vs 96 months (1–396)). The factors
associated with worse lung function were shown in Table
3. There was a positive correlation between BMI and lung
function, indicating that lower nutritional status was
related to lower FEV1, r2 = 0.21, P < 0.001 (Figure). The
median Chrispin-Norman score of severe lung disease
group was higher than nonsevere group (14 (6–22) vs
5.5 (0–20), P < 0.001). The proportion of patients with
F508del mutation in at least one allele was similar to
patients without F508del mutation in two groups (P =
0.46). The median FEV1% was lower in patients with CFrelated diabetes (CFRD) (38 (14–95) vs 66 (13–121), P =
0.042). The median FEV1% of the patients colonized with
P. aeruginosa was lower than others (56 (42–73) vs 68 (44–
91), P = 0.17), but it did not reach a statistical significance.
Dornase alpha use and physiotherapy rate were higher
in severe lung disease group (P = 0.008 and P < 0.001,
respectively). The median numbers of hospitalization for
intravenous antibiotic therapy for pulmonary exacerbation
in severe and nonsevere groups were 1 (0–12) vs 0 (0–3),
respectively (P = 0.04). Hospitalization at least once in
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Table 3. Factors associated with severe lung disease.
Group1: severe lung disease
(FEV1 <40% predicted) ( n = 18)

Group 2: nonsevere lung disease
(FEV1 ≥40% predicted) ( n = 58)

P-value

Female, n (%)

8 (44)

28 (48)

0.8

Age, mean±SD

27.1 ± 6.0

23.6 ± 4.7

0.013

Age of diagnosis, month, median (min-max)

102 (5–384)

96 (1–396)

0.4

BMI, mean±SD

18.5 ± 3.4

21.8 ± 3.6

0.001

CFRD, n (%)

6 (33)

5 (8)

0.009

Pancreatic insufficiency, n (%)
F508del at least one allel, n (%)

17 (94)

49 (84)

0.4

7 (38)

23 (39)

0.9

Chrispin norman score, median (min-max)

14 (6–22)

5.5 (0–20)

<0.001

Chronic P. aeruginosa, n (%)

5 (27)

18 (31)

0.7

Chronic MSSA, n (%)

5 (27)

22 (37)

0.4

Physiotherapy, n (%)

16 (88)

13 (22)

<0.001

Dornase alpha, n (%)

17 (94)

0.008

Hospitalization at least once in a year, n (%)

12 (66)

36 (62)
19 (32)

0.014

n= number, SD= standard deviation, BMI= body mass index, FEV1= forced expiratory volume in 1 s, min= minimum, max= maximum,
CFRD= cystic fibrosis related diabetes, P. aeruginosa= Pseudomonas aeruginosa, MSSA= Meticilin-sensitive Staphylococcus aureus

a year for intravenous antibiotic was more common in
severe group (12/18 (66%) vs 19/58 (32%), P = 0.014).
4. Discussion
To our knowledge, this is the first study evaluating risk
factors related with worse lung function in an adult
CF population in our country. We report that lower
BMI, older age, presence of CF-related diabetes, higher
Chrispin-Norman radiologic scores, use of dornase alpha
and physiotherapy and higher hospitalization rate for
intravenous antibiotic therapy are significantly associated
with severe lung disease.
Most of the patients were transferred from our pediatric
department. The median age at the time of diagnosis
was quite old (96 months) as compared with developed
countries (4 months in US and 4.1 months in Europe)
[2,3] and 10 patients were diagnosed during adulthood.
The positive impact of early diagnosis on the course of the
disease has already been known for years [10]. Therefore,
the disease is now included in the neonatal screening
program in many countries [11]. Turkey included CF in
the neonatal screening program in 2015. We hope that
early diagnosis with neonatal screening will reduce the
number of patients diagnosed in adulthood. In our study,
although the median age of diagnosis was not different
between groups, the mean age of the patients with severe
lung disease was higher. Longitudinal follow-up studies
have showed FEV1 decline in the natural progression of

948

the disease over years [12,13]. However, to discuss the
relationship between advanced age and poor lung capacity,
confounding factors should also be examined with larger
cohort studies. Women were found to be colonized earlier
with severe bacteria and had a decreased median life
expectancy compared with men previously [14], but in
our study, lung functions did not show difference between
sexes.
Most patients (63.2%) had BMI under the targeted
value. There was an association between BMI and FEV1%
predicted values. Many previous studies have emphasized
the importance of nutritional support with a high calorie
diet [15,16]. A study derived from European Cystic
Fibrosis Society Patient Registry showed that patients
with a lower BMI experienced a six-fold increased (95%
CI 5.0–7.3) severe lung disease (FEV1% predicted <40)
compared to patients with normal BMI [17]. Causality
cannot be proven on cross-sectional data, as whether
malnutrition is a cause or an effect of declining lung
function discussed previously in a review, there is a circle
of destruction consisting of lung damage from underlying
disease, increased work of breathing, decreased ventilatory
muscle mass, loss of respiratory muscles, and loss of
weight. Poor nutrition is reported to lead to loss of
muscle mass and to decreased diaphragm contractility
[18]. On the other hand, according to a systematic review
assessing nutritional intervention studies in cystic fibrosis,
a significant difference in pulmonary function could not
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Figure. The correlation between forced expiratory volume in 1 s (FEV1%) and body mass index
(BMI) values.

have been shown before and after nutritional interventions
[19]. Although almost 25% of our patients were categorized
as underweight, none of them accepted enteral nutrition
support via nasogastric or gastrostomy tubes. We thought
that lack of education and patients’ fear of the procedures
could be the underlying reasons for this problem.
Additionally, consistent with the literature, lower BMI
and lower FEV1 were observed in CFRD group in our study.
Diabetes is almost seen in 50% of CF patients in adulthood
[20]. Its negative impact on disease progression and lung
function is well-known; therefore, annual screening with
oral glucose tolerance test (OGTT) is recommended
since age of ten for CF patients [21]. In our CF unit,
adult patients have been evaluated for CFRD by OGTT
annually. Diabetes adversely affects disease prognosis
through various mechanisms. In human diabetic lungs
and in mouse models with CF as well, it was shown that
pulmonary capillary blood volume, lung elastic recoil, and
FEV1 are decreasing [22] in diabetes group. In a different
study, computed tomography scans of diabetic patients
were consistent with more significant airway thickening
and parenchymal changes [23]. In addition, inspiratory
muscle performance was found restricted in diabetic
patients [24]. Moreover, airway glucose concentration’s
effect on growth of respiratory pathogens was shown in a

study in diabetic CF patients [25]. The majority of the study
group (88%) had exocrine pancreas insufficiency. The
association between worse lung function and pancreatic
insufficiency was shown previously, but we could not
detect a similar result when we compared the groups [26].
In our study, F508del mutation frequency was quite
low compared to other European countries [3]. Cystic
fibrosis transmembrane conductance regulator mutation
distribution varies from country to country throughout the
world [27]. Previously it was shown that patients with class
1-2 mutations had lower spirometric values and higher
risk of developing severe lung disease [28]. Genotype is an
important determinant of clinical prognosis, but there are
also several risk factors which may affect clinical course of
the disease [26]. We could not detect genotype–phenotype
correlation in terms of lung functions in our patients.
Chrispin-Norman score was used for evaluating chest
radiographs, and the median value was higher in severe lung
disease group as we expected. Pseudomonas aeruginosa and
S. aureus were the most common pathogens isolated from
the patients in our study. Chronic P. aeruginosa infection
was shown to be associated with worse lung function
and a major predictor of morbidity and mortality during
both childhood and adulthood [29,30]. In our study, the
frequency of chronic infection did not differ between
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the two groups. Prevalence of fungal infection with
Aspergillus spp. was 23.6%. The clinical impact of fungi
on lung functions is not clear yet although cross-sectional
studies have shown negative effect on pulmonary function
[31]. We observed patients infected/colonized with
atypical pathogens such as Stenotrophomonas maltophilia,
Mycobacterium abscessus, and Achromobacter spp., and
their treatment and/or eradication of the pathogen was
challenging. The relationship between these agents and
lung function could not be investigated due to insufficient
patient numbers in groups.
Ninety-one percent of our patients with chronic P.
aeruginosa infection received inhaled tobramycin or
colistin. The beneficial effect of inhaled tobramycin and
oral azithromycin on chronic P. aeruginosa infection
was shown in several studies [32]. We could not detect
a significant difference between the groups in terms of
use of inhaled antibiotics. Dornase alfa was used as a
mucolytic agent in 69.7%, and it was more prescribed in
severe lung disease group. A study that compared lung
functions of US and UK showed that hypertonic saline
and dornase alfa were prescribed much more frequently
and the patients had better lung functions in the US [33].
There are several ongoing trials about CFTR-modulator
therapy in developed countries [34–36]. We could not use
these drugs in our patients because modulator treatments
are not covered by reimbursement yet.
Airway clearance techniques and chest physiotherapy
are the cornerstones of CF treatment and it is
recommended to all CF patients [37,38]. Although all
patients were consulted to physiotherapy department in
outpatient clinic, almost half of them were not performed
regular chest physiotherapy. However, patients in
the severe lung disease group were more compatible
to physiotherapy in our study or they needed more
physiotherapy.
The median number of hospitalization was higher
and hospitalization at least once in a year for intravenous
antibiotic therapy for pulmonary exacerbation was more
common in the severe group. It was previously shown that
higher pulmonary exacerbation rates requiring hospital
admission were associated with worse lung function [39].

Due to progressive lung disease, complications such as
hemoptysis and pneumothorax are increasing in older ages
[4]. The prevalence of massive or nonmassive hemoptysis was
40.8% and pneumothorax was 5.3% in our patient population
(Table 1). Although CF is one of the most common lung
transplantation indications worldwide, there was no
transplanted patient in our clinic due to lack of sufficient
experience in lung transplantation in CF in our country.
However, 12 (15.8%) patients have been on waiting list.
This is the first study focusing on the factors associated
with severe lung disease in a Turkish adult population with
CF. Although CF is a rare disease, as a reference center, we
evaluated the largest adult patient data. As a newly established
adult CF unit in our hospital, we collected the data regularly.
As a limitation of our study, this data belongs to a single
center and the patient number was not enough to evaluate
the risk factors with a regression model. Hopefully, as the
registry data increases over time, more information about
adult patients will be provided.
In conclusion, this study which includes the largest adult
population with CF in our country demonstrates that lower
BMI, older age, presence of CF-related diabetes, higher
radiologic scores, use of dornase alpha and physiotherapy,
and higher hospitalization rate for intravenous antibiotic
therapy are significantly associated with severe lung disease.
Respiratory failure is still the most common reason for
morbidity and mortality; therefore, for preventing lung
function decline, some factors like nutritional status of the
patients, presence of CFRD and chronic infections should be
seriously taken into account.
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